High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey-Reference-Cited by-同舟云学术

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

Published:2018-06-08 Issue:1 Volume:18 Page:
ISSN:1471-244X
Container-title:BMC Psychiatry
language:en
Short-container-title:BMC Psychiatry

Author:

Ono Shin,Sugai Takuro,Suzuki Yutaro,Yamazaki Manabu,Shimoda Kazutaka,Mori Takao,Ozeki Yuji,Matsuda Hiroshi,Sugawara Norio,Yasui-Furukori Norio,Okamoto Kurefu,Sagae Toyoaki,Someya Toshiyuki

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Link

http://link.springer.com/content/pdf/10.1186/s12888-018-1764-1.pdf

Reference38 articles.

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.

2. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903–12.

3. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.

4. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:4–14.

5. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:404–23.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activation of the PERK-CHOP signaling pathway during endoplasmic reticulum stress contributes to olanzapine-induced dyslipidemia;Acta Pharmacologica Sinica;2023-10-25

2. Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia;Frontiers in Psychiatry;2022-07-25

3. Associations between the number of antipsychotics prescribed and metabolic parameters in Japanese patients with schizophrenia;Psychiatry and Clinical Neurosciences Reports;2022-07-07

4. Differences in muscle strength, physical activity, and cardiometabolic risk factors between type 2 diabetic patients with and without benzodiazepines or antipsychotic medications;Heart and Mind;2022

5. Schizophrenia as a subject of competence of psychiatrist, narcologist, cardiologist, endocrinologist and pathologist;Neurology Bulletin;2021-01-26